Session 7: Future Directions for the Treatment of Relapsed/Refractory CLL

Co-Chair(s)

• 

  Arnon Kater, MD, PhD

  Deputy Head, Clinical Hematologist, Head of Research Lab
  Department of Hematology, Amsterdam UMC, University of Amsterdam, Cancer Center Amsterdam, Lymphoma and Myeloma Center Amsterdam
  Amsterdam, Netherlands
• 

  Danielle Brander, MD

  Assistant Professor of Medicine, Division of Hematologic Malignancies & Cellular Therapy
  Division of Hematologic Malignancies & Cellular Therapy
  Duke University Medical Center
  Durham, NC, United States

Presentations:

• 2:45 PM – 2:55 PM EDT

  Epcoritamab in Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia: Results From the Phase 1b/2 EPCORE CLL-1 Trial Expansion Cohort
  

  Primary Author; Presenting Author: Arnon P. Kater, MD, PhD – Department of Hematology, Amsterdam UMC, University of Amsterdam, Cancer Center Amsterdam, Lymphoma and Myeloma Center Amsterdam

  Co-Author: Herbert Eradat, MD – David Geffen School of Medicine at UCLA

  Co-Author: Carsten Utoft Niemann, MD, PhD – Department of Hematology, Copenhagen University Hospital Rigshospitalet, Denmark; Hematology Research Group, Danish Cancer Institute Research Center, Denmark; Department of Clinical Medicine, Copenhagen University

  Co-Author: Fritz Offner, MD, PhD – Universitair Ziekenhuis Gent

  Co-Author: Christian Bjørn Poulsen, MD – Zealand University Hospital

  Co-Author: Thor Høyer, MD – Aalborg University Hospital

  Co-Author: Mar Bellido, MD, PhD – University Medical Center Groningen and University of Groningen

  Co-Author: Mazyar Shadman, MD, MPH – Fred Hutchinson Cancer Center / University of Washington School of Medicine

  Co-Author: Toshihiko Oki, MD, PhD – AbbVie Inc.

  Co-Author: Alexandra Kuznetsova, PhD – Genmab

  Co-Author: Marcia Rios, MBA – Genmab

  Co-Author: Rebecca Valentin, MD, PhD – Genmab

  Co-Author: Hans Herluf Bentzen, MD – Aarhus University Hospital
• 2:55 PM – 3:05 PM EDT

  Bendamustine, Followed by Obinutuzumab, Acalabrutinib and Venetoclax in Patients (Pts) with Relapsed/Refractory Chronic Lymphocytic Leukemia (CLL): Updated Results of the CLL2-BAAG Trial of the German CLL Study Group (GCLLSG)
  

  Primary Author; Presenting Author: Paula Cramer, MD – Center for Integrated Oncology Aachen Bonn Cologne Duesseldorf; German CLL Study Group, University of Cologne

  Co-Author: Moritz Fürstenau, MD – Center for Integrated Oncology Aachen Bonn Cologne Duesseldorf; German CLL Study Group, University of Cologne

  Co-Author: Sandra Robrecht, PhD – Center for Integrated Oncology Aachen Bonn Cologne Duesseldorf; German CLL Study Group, University of Cologne

  Co-Author: Adam Giza, MSc – Department I of Internal Medicine, Center for Integrated Oncology Aachen Bonn Cologne and Duesseldorf, German CLL Study Group, Faculty of Medicine and University Hospital Cologne, University of Cologne

  Co-Author: Anna Fink, MD – Center for Integrated Oncology Aachen Bonn Cologne Duesseldorf; German CLL Study Group, University of Cologne

  Co-Author: Kirsten Fischer, MD – Center for Integrated Oncology Aachen Bonn Cologne Duesseldorf; German CLL Study Group, University of Cologne

  Co-Author: Petra Langerbeins, MD – Center for Integrated Oncology Aachen Bonn Cologne Duesseldorf; German CLL Study Group, University of Cologne

  Co-Author: Othman Al-Sawaf, MD – Center for Integrated Oncology Aachen Bonn Cologne Duesseldorf; German CLL Study Group, University of Cologne

  Co-Author: Eugen Tausch, MD – Department of Internal Medicine III, Ulm University

  Co-Author: Christof Schneider, MD – Department of Internal Medicine III, Ulm University

  Co-Author: Johannes Schetelig, Professor – Department I of Internal Medicine, University Hospital Carl Gustav Carus, Dresden, Germany

  Co-Author: Peter Dreger, MD – Department V of Internal Medicine, University Hospital Heidelberg

  Co-Author: Sebastian Böttcher, MD – Clinic for Internal Medicine III (Hematology, Oncology, Palliative Care), Rostock University Medical School

  Co-Author: Karl-Anton Anton Kreuzer, Professor – Department I of Internal Medicine, Center for Integrated Oncology Aachen Bonn Cologne and Duesseldorf, Faculty of Medicine and University Hospital Cologne, University of Cologne

  Co-Author: Anke Schilhabel, N/A – Department of Internal Medicine II, University Schleswig-Holstein

  Co-Author: Monika Brüggemann, Professor – Department of Internal Medicine II, University Schleswig-Holstein

  Co-Author: Michael Kneba, Professor – Department of Internal Medicine II, University Schleswig-Holstein

  Co-Author: Clemens M. Wendtner, MD – Department of Hematology, Oncology, Immunology, Palliative Care, Munich Clinic Schwabing

  Co-Author: Stephan Stilgenbauer, MD, PhD – Department of Internal Medicine III, Ulm University

  Co-Author: Barbara Eichhorst, MD – Center for Integrated Oncology Aachen Bonn Cologne Duesseldorf; German CLL Study Group, University of Cologne

  Co-Author: Michael Hallek, MD – Center for Integrated Oncology Aachen Bonn Cologne Duesseldorf; German CLL Study Group, University of Cologne
• 3:05 PM – 3:10 PM EDT

  Final 7-year Follow Up and Retreatment Substudy Analysis of MURANO: Venetoclax-Rituximab-Treated Patients With Relapsed/Refractory Chronic Lymphocytic Leukemia
  

  Primary Author; Presenting Author: John F. Seymour, MBBS, FRACP, PhD – Royal Melbourne Hospital, Peter MacCallum Cancer Centre and University of Melbourne

  Co-Author: Arnon P. Kater, MD, PhD – Department of Hematology, Amsterdam UMC, University of Amsterdam, Cancer Center Amsterdam, Lymphoma and Myeloma Center Amsterdam

  Co-Author: Rosemary Harrup, MD – Royal Hobart Hospital, University of Tasmania

  Co-Author: Thomas J. Kipps, MD, PhD – Center for Novel Therapeutics, Moores Cancer Center, University of California San Diego

  Co-Author: Barbara Eichhorst, MD – University Hospital of Cologne

  Co-Author: Carolyn J. Owen, MD – University of Calgary

  Co-Author: Sarit E. Assouline, MD, MSc, FRCPC – McGill University, Jewish General Hospital, Montreal

  Co-Author: Nicole Lamanna, MD – Columbia University Medical Center

  Co-Author: Tadeusz Robak, MD, PhD – Medical University of Lodz

  Co-Author: Javier de la Serna, MD, PhD – Hospital Universitario 12 de Octubre

  Co-Author: Ulrich Jaeger, MD – Medical University of Vienna

  Co-Author: Guillaume Cartron, MD, PhD – Centre Hospitalier Universitaire de Montpellier

  Co-Author: Marco Montillo, MD – Niguarda Cancer Center, ASST Grande Ospedale Metropolitano

  Co-Author: Clemens Mellink, MD, PhD – Amsterdam University Medical Centers

  Co-Author: Brenda Chyla, PhD – AbbVie Inc.

  Co-Author: Maria Thadani-Mulero, PhD – Roche Products Ltd.

  Co-Author: Marcus Lefebure, PhD – Roche Products Ltd.

  Co-Author: Yanwen Jiang, PhD – Genentech, Inc

  Co-Author: Rosemary Millen, PhD – Roche Products Ltd.

  Co-Author: Michelle Boyer, PhD – Genentech Inc
• 3:10 PM – 3:15 PM EDT

  Lisocabtagene maraleucel (liso-cel) in R/R chronic lymphocytic leukemia (CLL)/small lymphocytic lymphoma (SLL): primary analysis of TRANSCEND CLL 004
  

  Primary Author; Presenting Author: Tanya Siddiqi, MD – City of Hope National Medical Center

  Co-Author: David G. Maloney, MD, PhD – Fred Hutchinson Cancer Research Center

  Co-Author: Saad S. Kenderian, MB, ChB – Mayo Clinic

  Co-Author: Danielle M. Brander, MD – Duke University Medical Center

  Co-Author: Kathleen Dorritie, MD – UPMC Hillman Cancer Center, University of Pittsburgh

  Co-Author: Jacob Soumerai, MD – Center for Lymphoma, Massachusetts General Hospital Cancer Center

  Co-Author: Peter A. Riedell, MD – The David and Etta Jonas Center for Cellular Therapy, University of Chicago

  Co-Author: Nirav N. Shah, MD – Medical College of Wisconsin

  Co-Author: Rajneesh Nath, MD – Banner MD Anderson Cancer Center

  Co-Author: Bita Fakhri, MD, MPH – University of California San Francisco

  Co-Author: Deborah M. Stephens, DO – Lineberger Cancer Center, University of North Carolina

  Co-Author: Shuo Ma, MD, PhD – Robert H. Lurie Comprehensive Cancer Center of Northwestern University

  Co-Author: Tatyana Feldman, MD – John Theurer Cancer Center at Hackensack Meridian Health, HMH School of Medicine

  Co-Author: Scott R. Solomon, MD – Northside Hospital Cancer Institute

  Co-Author: Stephen J. Schuster, MD – Lymphoma Program, Abramson Cancer Center, University of Pennsylvania

  Co-Author: Serena K. Perna, PhD – Bristol Myers Squibb

  Co-Author: Sherilyn A. Tuazon, MD – Bristol Myers Squibb

  Co-Author: San-San Ou, MS – Bristol Myers Squibb

  Co-Author: Eniko Papp, PhD – Bristol Myers Squibb

  Co-Author: William G. Wierda, MD, PhD – University of Texas MD Anderson Cancer Center
• 3:15 PM – 3:25 PM EDT

  BTK Degraders - From Bench To Bedside
  

  Speaker: Alexey V. Danilov, MD, PhD – Department of Hematology and Transplantation;
  City of Hope National Medical Center
• 3:25 PM – 3:35 PM EDT

  Novel Inducers of Apoptosis
  

  Speaker: Deepa Sampath, PhD – Division of Hematopoietic Biology and Malignancy, MD Anderson Cancer Center
• 3:35 PM – 3:45 PM EDT

  How to Overcome T-Cell Dysfunction: Bispecifics
  

  Speaker: Arnon P. Kater, MD, PhD – Department of Hematology, Amsterdam UMC, University of Amsterdam, Cancer Center Amsterdam, Lymphoma and Myeloma Center Amsterdam
• 3:45 PM – 3:55 PM EDT

  How to Overcome T-Cell Dysfunction: Cellular Therapies
  

  Speaker: J. Joseph Melenhorst, PhD – Cleveland Clinic,Center for Immunotherapy & Precision Immuno-Oncology
• 3:55 PM – 4:10 PM EDT

  Panel Discussion With Interactivity and Audience Q&A